Virtual Reality Distracts Kids During Chemo

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

ATLANTA-Pediatric cancer patients often have anxiety before scheduled treatments or procedures, and treatment often requires normally active children to remain nearly motionless for extended periods of time. At the AFLAC Cancer Center at Children’s Healthcare of Atlanta, young cancer patients may find their treatment a little easier to bear thanks to an innovative program currently under way to examine the effects of virtual reality as a “distractor” for painful or uncomfortable medical procedures.

ATLANTA—Pediatric cancer patients often have anxiety before scheduled treatments or procedures, and treatment often requires normally active children to remain nearly motionless for extended periods of time. At the AFLAC Cancer Center at Children’s Healthcare of Atlanta, young cancer patients may find their treatment a little easier to bear thanks to an innovative program currently under way to examine the effects of virtual reality as a “distractor” for painful or uncomfortable medical procedures.

The research was conceived by psychologist Dr. Barbara Rothbaum of Emory University and computer expert Dr. Larry Hodges of the Georgia Institute of Technology, founders of Virtually Better, Inc.

The anecdotal evidence is promising so far, according to Rosemarie Lemos, a registered nurse with the Outpatient Clinic at the AFLAC Cancer Center. “One very anxious patient, as he was experiencing the virtual reality environment, asked me when I was going to perform the procedure,” she said. “My response was ‘I already did.’”

The initial study of the virtual reality system includes 50 patients between the ages of 8 and 18 undergoing chemotherapy via a central venous access device.

Recent Videos
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content